RE: Science Day27 Nov 2022 09:21
“My position is that I believe it works to some extent but I’m not convinced that we will get a massive spike in SP for the reasons that a lot of folk have posted on here only to get abused.”
£292m market cap
Dox market $1.5bn per annum.
Pre|CISION target market worth 10’s of billions per annum.
TMAC is based in Pre|CISION.
10s of billions is almost always a larger number than hundreds of millions. If you’re after an overnight spike to £10 on P1a ending then yes, that’s ridiculous. If biopsy data is presented to say it’s matched animal pre clin results or they’re a fair way better than standard Dox and we’ve cracked FAP then you really haven’t done any research if you think that won’t cause a massive increase (not a spike) in the SP. They will be two colossal milestones. If we stay independent there’s no reason this company can’t be worth 10s of billions if just one (of many) of the Pre|CISION drugs is a success. If we get bought before then it’ll be for many billions. See that word billions keeps popping up. This isn’t ramping. This is predicting an outcome based on current market sizes of drugs we are trialling and adding another prediction, that we will be successful in trials. What you’re after if news. Big spike. Rich. What investors here are expecting is news, rise, more news, rise, more news, rise. As news trickles in, as the trials continue, a Daewoong and LG progress also, as TMAC moved to pre clinic. License deals. AVA6000 to market. Etc etc. Theres a plethora of potential news here. And we’re fully funded to move through the next 2 years. So again. It’s not ramping is it. It’s analysing the potential.